anti-CD79b/CD20/CD3 trispecific antibody JNJ-80948543

{
  "id": "MLC-T-ONC-010447",
  "term": "anti-CD79b/CD20/CD3 trispecific antibody JNJ-80948543",
  "field": "Oncology and biomedicine",
  "definition": "A fully human effector-silent Fc immunoglobulin G1 (IgG1) trispecific antibody targeting the tumor-associated antigens (TAAs) B-cell antigen receptor complex-associated protein beta chain (CD79b; B-cell-specific glycoprotein B29) and cluster of differentiation 20 (CD20), and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD79b/CD20/CD3 trispecific antibody JNJ-80948543 targets and binds to CD79b- and/or CD20-expressing tumor B-cells and CD3 antigen on cytotoxic T lymphocytes (CTLs). This activates and redirects CTLs to CD79b- and/or CD20-expressing tumor B cells, resulting in CTL-mediated killing of tumor cells. CD79b, a critical receptor for successful B-cell development and part of the B-cell receptor (BCR) signaling complex, is widely expressed in certain subtypes of B-cell lymphomas. CD20 is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.",
  "synonyms": [
    "anti-CD79b/anti-CD20/anti-CD3 trispecific antibody JNJ-80948543",
    "CD79b/CD20/CD3 T-cell engager JNJ-80948543",
    "CD79b/CD20/CD3 TCE JNJ-80948543"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-cd79b-cd20-cd3-trispecific-antibody-jnj-80948543/"
}